Cargando…

Novel Tocolytic Strategy: Modulating Cx43 Activity by S-Nitrosation

Currently available tocolytics are ineffective at significantly delaying preterm birth. This is due in part to our failure to better understand the mechanisms that drive spontaneous preterm labor (sPTL). Cyclic nucleotides are not the primary contributors to myometrial quiescence, but instead nitric...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnett, Scott D., Asif, Hazik, Anderson, Mitchell, Buxton, Iain L. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Pharmacology and Experimental Therapeutics 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919864/
https://www.ncbi.nlm.nih.gov/pubmed/33384302
http://dx.doi.org/10.1124/jpet.120.000427
_version_ 1783658197085585408
author Barnett, Scott D.
Asif, Hazik
Anderson, Mitchell
Buxton, Iain L. O.
author_facet Barnett, Scott D.
Asif, Hazik
Anderson, Mitchell
Buxton, Iain L. O.
author_sort Barnett, Scott D.
collection PubMed
description Currently available tocolytics are ineffective at significantly delaying preterm birth. This is due in part to our failure to better understand the mechanisms that drive spontaneous preterm labor (sPTL). Cyclic nucleotides are not the primary contributors to myometrial quiescence, but instead nitric oxide (NO)-mediated protein S-nitrosation (SNO) is integral to the relaxation of the tissue. Connexin-43 (Cx43), a myometrial “contractile-associated protein” that functions as either a gap junction channel or an hemichannel (HC), was the focus of this study. Protein analysis determined that Cx43 is downregulated in sPTL myometrium. Furthermore, Cx43 is S-nitrosated by NO, which correlates with an increase of phosphorylated Cx43 at serine 368 (Cx43-pS368 -gap junction inhibition) as well as an increase in the HC open-state probability (quiescence). Pharmacologic inhibition of Cx43 with 18β-glycyrrhetinic acid (18β-GA) exhibits a negative inotropic effect on the myometrium in a dose-dependent manner, as does administration of nebivolol, an NO synthase activator that increases total protein SNOs. When 18β-GA and nebivolol were coadministered at their IC(50) values, the effect on contractile dynamics was additive and all but eliminated contractions. The development of new tocolytics demands a better understanding of the underlying mechanisms of sPTL. Here it has been shown that 18β-GA and nebivolol leverage dysregulated pathways in the myometrium, resulting in a novel approach for the treatment of sPTL. SIGNIFICANCE STATEMENT: Although there are many known causes of preterm labor (PTL), the mechanisms of “spontaneous” PTL (sPTL) remain obfuscated, which is why treating this condition is so challenging. Here we have identified that connexin-43 (Cx43), an important contractile-associated protein, is dysregulated in sPTL myometrium and that the pharmacologic inhibition of Cx43 and its S-nitrosation with 18β-glycyrrhetinic acid and nebivolol, respectively, significantly blunts contraction in human myometrial tissue, presenting a novel approach to tocolysis that leverages maladjusted pathways in women who experience sPTL.
format Online
Article
Text
id pubmed-7919864
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The American Society for Pharmacology and Experimental Therapeutics
record_format MEDLINE/PubMed
spelling pubmed-79198642021-03-09 Novel Tocolytic Strategy: Modulating Cx43 Activity by S-Nitrosation Barnett, Scott D. Asif, Hazik Anderson, Mitchell Buxton, Iain L. O. J Pharmacol Exp Ther Drug Discovery and Translational Medicine Currently available tocolytics are ineffective at significantly delaying preterm birth. This is due in part to our failure to better understand the mechanisms that drive spontaneous preterm labor (sPTL). Cyclic nucleotides are not the primary contributors to myometrial quiescence, but instead nitric oxide (NO)-mediated protein S-nitrosation (SNO) is integral to the relaxation of the tissue. Connexin-43 (Cx43), a myometrial “contractile-associated protein” that functions as either a gap junction channel or an hemichannel (HC), was the focus of this study. Protein analysis determined that Cx43 is downregulated in sPTL myometrium. Furthermore, Cx43 is S-nitrosated by NO, which correlates with an increase of phosphorylated Cx43 at serine 368 (Cx43-pS368 -gap junction inhibition) as well as an increase in the HC open-state probability (quiescence). Pharmacologic inhibition of Cx43 with 18β-glycyrrhetinic acid (18β-GA) exhibits a negative inotropic effect on the myometrium in a dose-dependent manner, as does administration of nebivolol, an NO synthase activator that increases total protein SNOs. When 18β-GA and nebivolol were coadministered at their IC(50) values, the effect on contractile dynamics was additive and all but eliminated contractions. The development of new tocolytics demands a better understanding of the underlying mechanisms of sPTL. Here it has been shown that 18β-GA and nebivolol leverage dysregulated pathways in the myometrium, resulting in a novel approach for the treatment of sPTL. SIGNIFICANCE STATEMENT: Although there are many known causes of preterm labor (PTL), the mechanisms of “spontaneous” PTL (sPTL) remain obfuscated, which is why treating this condition is so challenging. Here we have identified that connexin-43 (Cx43), an important contractile-associated protein, is dysregulated in sPTL myometrium and that the pharmacologic inhibition of Cx43 and its S-nitrosation with 18β-glycyrrhetinic acid and nebivolol, respectively, significantly blunts contraction in human myometrial tissue, presenting a novel approach to tocolysis that leverages maladjusted pathways in women who experience sPTL. The American Society for Pharmacology and Experimental Therapeutics 2021-03 2021-03 /pmc/articles/PMC7919864/ /pubmed/33384302 http://dx.doi.org/10.1124/jpet.120.000427 Text en Copyright © 2021 by The Author(s) http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the CC BY-NC Attribution 4.0 International license (http://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Drug Discovery and Translational Medicine
Barnett, Scott D.
Asif, Hazik
Anderson, Mitchell
Buxton, Iain L. O.
Novel Tocolytic Strategy: Modulating Cx43 Activity by S-Nitrosation
title Novel Tocolytic Strategy: Modulating Cx43 Activity by S-Nitrosation
title_full Novel Tocolytic Strategy: Modulating Cx43 Activity by S-Nitrosation
title_fullStr Novel Tocolytic Strategy: Modulating Cx43 Activity by S-Nitrosation
title_full_unstemmed Novel Tocolytic Strategy: Modulating Cx43 Activity by S-Nitrosation
title_short Novel Tocolytic Strategy: Modulating Cx43 Activity by S-Nitrosation
title_sort novel tocolytic strategy: modulating cx43 activity by s-nitrosation
topic Drug Discovery and Translational Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919864/
https://www.ncbi.nlm.nih.gov/pubmed/33384302
http://dx.doi.org/10.1124/jpet.120.000427
work_keys_str_mv AT barnettscottd noveltocolyticstrategymodulatingcx43activitybysnitrosation
AT asifhazik noveltocolyticstrategymodulatingcx43activitybysnitrosation
AT andersonmitchell noveltocolyticstrategymodulatingcx43activitybysnitrosation
AT buxtoniainlo noveltocolyticstrategymodulatingcx43activitybysnitrosation